SCHEMBL4478838

SCHEMBL4478838

COc1cc2nccc(Oc3ccc(NC(=O)NCCC(C)(C)C)c(C)c3)c2cc1OC

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 14/20 0.66
KDR P35968 14/20 0.66
FGFR2 P21802 2/20 0.58
KIT P10721 2/20 0.58
AXL P30530 1/20 0.58
MET P08581 5/20 0.54
RIPK2 O43353 1/20 0.54
STK10 O94804 1/20 0.54
ABL1 P00519 1/20 0.54
LCK P06239 1/20 0.54
LYN P07948 1/20 0.54
RET P07949 1/20 0.54
PDGFRB P09619 1/20 0.54
BCR P11274 1/20 0.54
FGFR1 P11362 1/20 0.54
SRC P12931 1/20 0.54
FLT1 P17948 1/20 0.54
MAPK3 P27361 1/20 0.54
HTR2A P28223 1/20 0.54
MAPK1 P28482 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4489090 0.93 PDGFRA (0.60) PDGFRAKDRFGFR2KITAXL
SCHEMBL4465227 0.90 PDGFRA (0.72) PDGFRAKDRFGFR2KITAXL
SCHEMBL4472865 0.90 KDR (0.67) PDGFRAKDRFGFR2KITAXL
Hydrochloric Acid SCHEMBL5097587 0.89 PDGFRA (0.71) PDGFRAKDRFGFR2KITAXL
Hydrochloric Acid SCHEMBL5088438 0.89 KDR (0.66) PDGFRAKDRFGFR2KITAXL
SCHEMBL4468127 0.89 PDGFRA (0.58) PDGFRAKDRFGFR2KITAXL
SCHEMBL4468966 0.88 SRC (0.52) PDGFRAKDRFGFR2KITAXL
SCHEMBL4469272 0.87 PDGFRA (0.62) PDGFRAKDRFGFR2KITAXL
SCHEMBL4468642 0.87 PDGFRA (0.73) PDGFRAKDRMET
SCHEMBL4482204 0.86 FGFR2 (0.57) PDGFRAKDRFGFR2KITAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same KIRIN BEER KABUSHIKI KAISHA (JP) 2008-08-28 US disclosed
EP-1566379-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2005-08-24 EP disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 PDGFRA 372/4885KDR 211/4885FGFR2 2/4885
US-20080207617-A1 Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same FLT3, TYRO3, ABL1 PDGFRA 229/4885KDR 148/4885FGFR2 1020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.